PAI
CRSP icon

Palo Alto Investors’s CRISPR Therapeutics CRSP Stock Holding History

Palo Alto Investors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.88M Sell
39,605
-1,621
-4% -$85.5K 0.29% 38
2025
Q4 		$2.16M Hold
41,226
– – 0.3% 36
2025
Q3 		$2.67M Sell
41,226
-3,399
-8% -$195K 0.49% 29
2025
Q2 		$2.17M Buy
+44,625
New +$1.73M 0.46% 28

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Palo Alto Investors's CRSP Position: Q1 2026 in Review

Palo Alto Investors reduced its CRISPR Therapeutics (CRSP) stake by 3.9% in Q1 2026, selling an estimated $85.5K and leaving 39,605 shares worth $1.88M. The position accounts for 0.29% of the portfolio, ranked #38.

Palo Alto Investors first reported a position in CRSP in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.67M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Palo Alto Investors held 39,605 shares of CRISPR Therapeutics worth $1.88M as of Q1 2026.
  • Palo Alto Investors sold 1,621 CRISPR Therapeutics shares in Q1 2026, an estimated $85.5K.
  • CRISPR Therapeutics made up 0.29% of Palo Alto Investors's portfolio in Q1 2026, its #38 holding.
  • Palo Alto Investors first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Palo Alto Investors's CRISPR Therapeutics position peaked at $2.67M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.